Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $74.7M | $25.3M | $20.7M | $4.4M | $9.2M | |
| Gross Profit | $26M | $11.1M | $15.6M | $2.7M | $8.1M | |
| Operating Income | -$5.3M | -$10.1M | -$20.4M | -$1.3M | -$8.8M | |
| EBITDA | -$610.9K | -$7M | -$19.7M | -$1.1M | -$8.7M | |
| Diluted EPS | -$15.56 | -$9.33 | -$3.54 | -$1.56 | $0.75 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.8M | $18.8M | $24.9M | $6.8M | $220.3M | |
| Total Assets | $29.2M | $49.1M | $65.2M | $18.6M | $419.7M | |
| Current Liabilities | $4.2M | $11.7M | $20M | $9.8M | $64.6M | |
| Total Liabilities | $4.4M | $22.1M | $37.7M | $13.6M | $208.9M | |
| Total Equity | $24.8M | $27M | $27.6M | $5M | $210.8M | |
| Total Debt | $1.2M | $15.8M | $27.6M | $9.9M | $150.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.1M | -$4.8M | -$23.9M | -$2M | -$17.4M | |
| Cash From Investing | $218.4K | $4.8M | -$135.5M | $5.8M | -$30.3M | |
| Cash From Financing | -$1.9M | -$6.4M | $159.8M | -$2.7M | $47M | |
| Free Cash Flow | -$2.2M | -$5.6M | -$24.1M | -$2.1M | -$17.4M | |
Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. Its brands include LuckyTail, Prax, Cure Mushrooms, Moonwlkr, and Gumi Labs. The company was founded on September 5, 2018 and is headquartered in Tampa, FL.
In the current month, UPXI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UPXI average analyst price target in the past 3 months is $16.00.
According to analysts, the consensus estimate is that Upexi, Inc. share price will rise to $16.00 per share over the next 12 months.
Analysts are divided on their view about Upexi, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Upexi, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
The price target for Upexi, Inc. over the next 1-year time period is forecast to be $16.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Upexi, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
You can purchase shares of Upexi, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Upexi, Inc. shares.
Upexi, Inc. was last trading at $1.85 per share. This represents the most recent stock quote for Upexi, Inc.. Yesterday, Upexi, Inc. closed at $1.99 per share.
In order to purchase Upexi, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Market Cap: $4.5T
P/E Ratio: 63x
Market Cap: $4T
P/E Ratio: 36x
Market Cap: $3.8T
P/E Ratio: 39x
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
UniFirst Corp. [UNF] is up 0.77% over the past day.